ClinicalTrials.gg
WithdrawnNCT07518121BRIDGE-BRUpdated Nov 20, 2026

A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil

A Phase 1 interventional study of Efsubaglutide Alfa Injection and Placebo in Diabete Type 2, sponsored by Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Withdrawn at 1 site in Brazil. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
PK bridging has been exempted
Updated Nov 20, 2026Now WithdrawnEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil — 35 open to participants now, 44 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Brazil.

Enrollment
290th of 295
0 · median 329
Started
2026
with 22 others
Phase 1
7 of 317
none open now
Registered
302nd of 317
by date

Among the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil, this one is the 290th largest by enrollment of the 295 interventional ones that give a count, is one of 23 that started in 2026, is one of 7 in phase 1, and was the 302nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil, or all of them as a file.
02

Study summary

This is a Phase I, randomized, double-blind, placebo-controlled, single-dose study in healthy adult participants in Brazil to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of YN-011. Participants will be randomized to receive a single subcutaneous dose of YN-011 1 mg, YN-011 3 mg, or matching placebo. The study includes screening, approximately 2 days of study-site confinement from the day before dosing to 24 hours after dosing, and outpatient follow-up for 4 weeks. Assessments include safety monitoring, PK blood sampling, PD evaluations, and immunogenicity testing.

Read the detailed description

This is a Phase I, randomized, double-blind, placebo-controlled, single-dose, parallel-group study in healthy adult participants in Brazil to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of YN-011 following subcutaneous administration.

The study will be conducted at a single clinical study site in Brazil and will enroll approximately 48 healthy adult participants. Participants will be randomized into 2 dose cohorts, a 1 mg cohort and a 3 mg cohort. Within each cohort, participants will be randomized in a 5:1 ratio to receive a single subcutaneous dose of YN-011 or matching placebo. Overall, the study will include 3 treatment groups: YN-011 1 mg, YN-011 3 mg, and placebo. The placebo will be matched in appearance and administered using the same device format in order to maintain blinding.

The main objectives of the study are to assess the safety and tolerability of YN-011 after single-dose administration in healthy adult participants, to characterize its PK profile, to evaluate selected PD effects, and to assess immunogenicity. Safety evaluations will include adverse events, clinical laboratory tests, vital signs, electrocardiograms, physical examinations, and other appropriate clinical assessments. PK assessments will characterize the concentration-time profile of YN-011 after dosing. PD assessments will evaluate the biologic effects of YN-011 after administration. Immunogenicity assessments will evaluate whether participants develop an immune response to YN-011.

The study includes a screening period of up to 4 weeks, a study-site confinement period of approximately 2 days, and an outpatient follow-up period of 4 weeks, for a maximum total study duration of approximately 8 weeks per participant. Participants will be admitted to the clinical study site on the day before dosing and will undergo pre-dose assessments to confirm continued eligibility. On Day 1, participants will receive a single subcutaneous injection of YN-011 1 mg, YN-011 3 mg, or matching placebo in the abdomen using a prefilled auto-injector.

During the confinement period, participants will remain under close clinical observation and will receive a controlled diet with specified fasting and fluid intake restrictions around dosing. After completion of the post-dose confinement period, participants will be discharged from the clinical study site and will return for scheduled outpatient follow-up visits for PK blood sampling, safety monitoring, PD evaluations, and immunogenicity assessments.

The results of this study are expected to provide clinical information on the safety, PK, PD, and immunogenicity profile of single-dose YN-011 in healthy adult participants in Brazil.

03

Conditions studied

  • Diabete Type 2

Keywords

  • Efsubaglutide Alfa
  • Phase 1
  • Healthy Volunteers
  • Pharmacokinetics
  • Brazil
  • Bridging Study
  • GLP-1 Receptor Agonist
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female adults, aged 18-45 years (both inclusive) at the time of signing the form (ICF).
  2. (BMI) between 18-28 kg/m2 (both inclusive). Male participants must weigh no less than 50 kg, and female participants must weigh no less than 45 kg.
  3. Voluntary participation in this study, as documented by the written signature of two copies of the ICF.
  4. Negative serum pregnancy test for women of (WOCBP) during screening period. WOCBP and fertile male participants with WOCBP partners must use highly effective methods without planning to become pregnant or to donate sperm or eggs throughout this study (from signing the ICF to at least 3 months after completion of this study).
  5. Be able to maintain good communication with the investigators and comply with all requirements of protocol to complete all trial procedures.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected allergy to the medicinal product, its components or drugs of the same class, or a drug allergy, or a history of atopic allergic disease.
  2. Previously or currently diagnosed diabetes mellitus (T1D or T2D) or prediabetes, according to the diagnostic criteria of the Brazilian Diabetes Society (SBD) guideline, defined by any of the following laboratory findings:

    • FPG ≥126 mg/dL or ≥7.0 mmol/L ;
    • FPG 100-125 mg/dL or 5.6 -6.9 mmol/L (prediabetes);
    • ≥ 6.5% or ≥48 mmol/mol;
    • HbA1c 5.7-6.4% or 39-47 mmol/mol (prediabetes).
  3. History of clinically significant endocrine disorders that may affect glucose metabolism, body weight, or drug PK, including but not limited to Cushing's syndrome; acromegaly; pheochromocytoma; untreated or uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism); polycystic ovary syndrome (PCOS) with metabolic abnormalities; adrenal insufficiency or other adrenal disorders; pituitary disorders affecting hormonal regulation.
  4. History of acute or chronic pancreatitis, symptomatic gallbladder disease (those who have recovered from cholecystectomy and have no sequelae after treatment are allowable to be enrolled), pancreatic injury or other high-risk factors that may lead to pancreatitis, or screening serum amylase or lipase >2X (ULN).
  5. History of significant gastrointestinal (GI) disorders (e.g., gastroparesis, active ulcers within 6 months, or long-term use of medications that directly affect GI motility, or GI surgery within 6 months prior to screening.
  6. History or presence of hepatic, renal, cardiovascular, neurological, psychiatric, psychological or immunological disorders.
  7. Clinically significant abnormalities in physical examination, vital signs, laboratory tests, or 12-lead at screening, and investigators consider that these abnormalities may affect participant's safety or study results. ECG abnormalities including but not limited to: second- or third-degree atrioventricular block; long syndrome or QTcF > 450 ms (males) or > 470 ms (females). (If the QTcF > 450 ms (males) or > 470 ms (females), two additional ECG measurements should be repeated, and the mean of the three values should be used to determine the participant's eligibility.); left bundle branch block;Wolff-Parkinson-White syndrome; Or other clinically significant 12-lead ECG abnormalities requiring treatment.
  8. Use of any prescription or over-the-counter (OTC) medications, traditional Chinese medicine within 12 months prior to screening that may confound PK, PD, or safety assessments.
  9. Personal or family history of thyroid C-cell tumors including medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia type 2 (MEN2), or presence of hyperthyroidism or hypothyroidism that has not been controlled with a stable medication dose (defined as a stable dose for at least 3 months or longer).
  10. Positive test results for (HIV) antibody, surface antigen (HBSAg) and HBV-deoxyribonucleric adic (DNA) ≥ lab-specific ULN (for those with positive result on HBsAg, HBV-DNA test will be performed), antibody (HCV-Ab) and HCV-ribonucleric acid (RNA), participant can be eligible at the discretion of the investigator if HCV-Ab positive and HCV RNA negative, or Treponema pallidum antibody (TP-Ab).
  11. Pregnant or breastfeeding women.
  12. Donation or loss of ≥400 mL of blood within 3 months prior to screening.
  13. History of drug abuse within 1 year prior to screening, or positive drug abuse screening test (including amphetamines (AMP), cocaine (COC), tetrahydrocannabinol (THC), morphine (MOP), benzodiazepines (BZO), and methamphetamines (MET), any one or more of which tested positive).
  14. Consumption of more than 14 units of alcohol per week within 6 months prior to screening (1 unit of alcohol equivalent to 360 mL of beer or 45 mL of spirits with an alcohol content of 40% or 150 mL of wine), or consumption of alcohol-containing products within 48 hours before administration, or positive breath alcohol test before administration.
  15. Participation in other clinical trials of vaccines, medical devices, or other drugs within 12 months prior to screening
  16. Major surgery within 4 weeks prior to screening, or planned major surgery during the study.
  17. Participant with systolic blood pressure (SBP) \< 90 mmHg or > 140 mmHg, or diastolic blood pressure (DBP) \< 50 mmHg or > 90 mmHg after resting in a sitting position, or heart rate (HR) \< 50 beats per minute (BPM) or > 100 bpm at rest in sitting position at the screening.
  18. Any other factors that may affect participation in this study at the discretion of the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    YN-011 1mg

    Drug: Efsubaglutide Alfa Injection

  • Experimental
    YN-011 3mg

    Drug: Efsubaglutide Alfa Injection

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugEfsubaglutide alfaStudies of Efsubaglutide alfaEfsubaglutide alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Efsubaglutide alfa will be administered as a single subcutaneous injection at a dose of 1 mg or 3 mg on Day 1 in healthy adult participants. The study drug will be administered in the abdomen using a prefilled auto-injector.

  • DrugPlacebo

    Matching placebo will be administered as a single subcutaneous injection on Day 1 in healthy adult participants. Placebo is identical in appearance and presentation to efsubaglutide alfa and will be administered in the abdomen using a matching prefilled auto-injector.

06

What researchers measure

Primary outcomes

  1. Concentration (Cmax) of YN-011 maximum Observed Plasma

    Time frame: Predose through Day 29

  2. Concentration (Tmax) of YN-011 Time to Maximum Observed Plasma

    Time frame: Predose through Day 29

  3. Concentration (AUC0-t) of YN-011 Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable

    Time frame: Predose through Day 29

  4. Concentration of Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of YN-011

    Time frame: Predose through Day 29

  5. Terminal Elimination Half-Life (t1/2) of YN-011

    Time frame: Predose through Day 29

Secondary outcomes

  1. Rate of Incidence and severity of adverse events

    Incidence and severity of adverse events, including treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).

    Time frame: From informed consent through Day 29

  2. Rate of Clinically significant changes in vital signs, clinical laboratory tests, and 12-lead electrocardiograms

    Clinically significant changes in vital signs, clinical laboratory tests, including hematology, biochemistry, amylase, lipase, and urinalysis, and 12-lead electrocardiograms.

    Time frame: Baseline through Day 29

  3. Change rate of from baseline in fasting plasma glucose

    Time frame: Baseline through Day 29

  4. Change Rate of From Baseline in Body Weight

    Time frame: Baseline through Day 29

  5. Incidence rate of anti-drug antibodies and neutralizing antibodies

    Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs), if ADA positive.

    Time frame: Baseline through Day 29

  6. Correlation Between AUC0-inf of YN-011 and Change From Baseline in Fasting Plasma Glucose at Day 29

    Time frame: Baseline and Day 29

  7. Correlation between AUC0-inf of YN-011 and change from baseline in body weight at Day 29

    Time frame: Baseline and Day 29

  8. Comparison of AUC0-inf of YN-011 Between Healthy Adult Brazilian Participants and Chinese Phase I Healthy Participants

    Comparison of AUC0-inf of YN-011 between healthy adult Brazilian participants in this study and existing healthy-participant data from the Chinese Phase I clinical program.

    Time frame: Predose through Day 29

  9. Comparison of AUC0-t of YN-011 Between Healthy Adult Brazilian Participants and Chinese Phase I Healthy Participants

    Comparison of AUC0-t of YN-011 between healthy adult Brazilian participants in this study and existing healthy-participant data from the Chinese Phase I clinical program.

    Time frame: Predose through Day 29

  10. Comparison of Cmax of YN-011 Between Healthy Adult Brazilian Participants and Chinese Phase I Healthy Participants

    Comparison of Cmax of YN-011 between healthy adult Brazilian participants in this study and existing healthy-participant data from the Chinese Phase I clinical program.

    Time frame: Predose through Day 29

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Aug 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Apr 8, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Aug 1, 2026
CompletionEst.
Oct 31, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn PK bridging has been exempted
changed Nov 20, 2026
Enrollment
48 (estimated)→0 (actual)
Nov 20, 2026
Primary outcomes
4 edited
What changed in the outcomes
  • EditedMaximum Observed Plasma Concentration (Cmax) of YN-011 maximum Observed PlasmaTime frame: Predose through Day 29
  • EditedTime to Maximum Observed Plasma Concentration (Tmax) of YN-011 Time to Maximum Observed PlasmaTime frame: Predose through Day 29
  • EditedConcentration (AUC0-t) of YN-011 Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of YN-011Time frame: Predose through Day 29
  • EditedConcentration of Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of YN-011Time frame: Predose through Day 29
Nov 20, 2026
Secondary outcomes
5 edited
What changed in the outcomes
  • EditedRate of Incidence and severity of adverse eventsTime frame: From informed consent through Day 29
  • EditedRate of Clinically significant changes in vital signs, clinical laboratory tests, and 12-lead electrocardiogramsTime frame: Baseline through Day 29
  • EditedChange rate of from baseline in fasting plasma glucoseTime frame: Baseline through Day 29
  • EditedChange Rate of From Baseline in Body WeightTime frame: Baseline through Day 29
  • EditedIncidence rate of anti-drug antibodies and neutralizing antibodiesTime frame: Baseline through Day 29
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Withdrawn
    Why stopped PK bridging has been exempted
    Enrollment 48 (estimated)→0 (actual)
    Primary outcomes 4 edited
    What changed in the outcomes
    • EditedMaximum Observed Plasma Concentration (Cmax) of YN-011 maximum Observed PlasmaTime frame: Predose through Day 29
    • EditedTime to Maximum Observed Plasma Concentration (Tmax) of YN-011 Time to Maximum Observed PlasmaTime frame: Predose through Day 29
    • EditedConcentration (AUC0-t) of YN-011 Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t) of YN-011Time frame: Predose through Day 29
    • EditedConcentration of Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of YN-011Time frame: Predose through Day 29
    Secondary outcomes 5 edited
    What changed in the outcomes
    • EditedRate of Incidence and severity of adverse eventsTime frame: From informed consent through Day 29
    • EditedRate of Clinically significant changes in vital signs, clinical laboratory tests, and 12-lead electrocardiogramsTime frame: Baseline through Day 29
    • EditedChange rate of from baseline in fasting plasma glucoseTime frame: Baseline through Day 29
    • EditedChange Rate of From Baseline in Body WeightTime frame: Baseline through Day 29
    • EditedIncidence rate of anti-drug antibodies and neutralizing antibodiesTime frame: Baseline through Day 29
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07518121
Lead sponsor
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Apr 8, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Aug 1, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Nov 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efsubaglutide alfa

Start the discussion